Kura Oncology, Inc. (KURA)
10.66
+0.14
(+1.28%)
USD |
NASDAQ |
Oct 07, 16:00
10.70
+0.04
(+0.33%)
After-Hours: 20:00
Kura Oncology EPS Diluted (Quarterly) : -0.769 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.769 |
| March 31, 2026 | -0.8276 |
| December 31, 2025 | -0.9199 |
| September 30, 2025 | -0.8456 |
| June 30, 2025 | -0.7549 |
| March 31, 2025 | -0.657 |
| December 31, 2024 | -0.2205 |
| September 30, 2024 | -0.6257 |
| June 30, 2024 | -0.5868 |
| March 31, 2024 | -0.5903 |
| December 31, 2023 | -0.5532 |
| September 30, 2023 | -0.4998 |
| June 30, 2023 | -0.5326 |
| March 31, 2023 | -0.4981 |
| December 31, 2022 | -0.4885 |
| September 30, 2022 | -0.5308 |
| June 30, 2022 | -0.5215 |
| March 31, 2022 | -0.4872 |
| December 31, 2021 | -0.492 |
| September 30, 2021 | -0.5029 |
| June 30, 2021 | -0.5079 |
| March 31, 2021 | -0.4635 |
| December 31, 2020 | -0.4452 |
| Date | Value |
|---|---|
| September 30, 2020 | -0.4214 |
| June 30, 2020 | -0.3968 |
| March 31, 2020 | -0.423 |
| December 31, 2019 | -0.3941 |
| September 30, 2019 | -0.3623 |
| June 30, 2019 | -0.3839 |
| March 31, 2019 | -0.3652 |
| December 31, 2018 | -0.4227 |
| September 30, 2018 | -0.3971 |
| June 30, 2018 | -0.45 |
| March 31, 2018 | -0.4588 |
| December 31, 2017 | -0.3653 |
| September 30, 2017 | -0.38 |
| June 30, 2017 | -0.40 |
| March 31, 2017 | -0.39 |
| December 31, 2016 | -0.38 |
| September 30, 2016 | -0.37 |
| June 30, 2016 | -0.36 |
| March 31, 2016 | -0.36 |
| December 31, 2015 | -0.42 |
| September 30, 2015 | -0.57 |
| June 30, 2015 | -0.2574 |
| March 31, 2015 | -0.2063 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -0.0737 |
| Fortress Biotech, Inc. | -0.0779 |
| Spero Therapeutics, Inc. | -0.1648 |
| Gossamer Bio, Inc. | -6.124 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -68.33M |
| Revenue (Quarterly) | 20.87M |
| Total Expenses (Quarterly) | 89.20M |
| Enterprise Value | 442.12M |
| Gross Profit Margin (Quarterly) | 97.07% |
| Profit Margin (Quarterly) | -327.3% |
| Earnings Yield | -31.52% |
| Normalized Earnings Yield | -31.52 |